- О проекте
- Результаты и Награды
- Партнерские программы
- Международные услуги
Svitlana Pavliy, доцент, кандидат биологических наук
Львовский Национальный медицинский университет им. Д. Галицкого, Украина
Участник первенства: Национальное первенство по научной аналитике - "Украина";
Investigated three newly created compound of fluorene derivatives (FL4, P6, P7) on antibacterial activity against Gram-positive and Gram-negative bacteria. Found that these compounds were effective against Gram-positive bacterial strains.
Keywords: fluorene derivatives, bacteria, antibacterial activity.
The introduction of new medical practice chemotherapy drugs and wide-spectrum antibiotics has created prospects for the successful treatment of many diseases of microbial etiology, especially viral and bacterial. However, over time the practical activities initially quite effective chemotherapy drugs over the past decade have dramatically decreased. The reason for this, according to most researchers, is the emergence and widespread dissemination of resistance to these drugs, microorganisms, and most often the MDR strains of bacteria [1-4].
Formation and intensive distribution in terms of health care facilities of drug-resistant microorganisms associated with the production of β-lactamases, as well as increasing the adaptive adhesive properties and virulence of competitiveness that in the end gives them a selective advantage in the microbiocenosis [5-7]. The problem of nosocomial infections is that in recent years, has gained great importance for all countries of the world. The share nosocomial infection ranges from 2 to 30% depending on the profile of medical institutions and the objectivity of their registration.
At the Department of Pharmaceutical Chemistry of LNMU Danylo Galician Danylo Halytsky Lviv National Medical University, M.D. Lubov Petrukh synthesized new TB drug Flurenizyd, and in 2000 established its commercial production on "Kiev Vitamin Factory." The effectiveness of this drug evidenced by the data in the literature [13-15]. Over the decades, was synthesized and patented several newly synthesized derivatives of fluorenizide, including the three investigated compounds that are promising in terms of their antibacterial activity.
Objects of research: 3 fluorene derivatives that synthesized by the head of Department of Pharmaceutical Chemistry, Faculty of Continuing Education of Danylo Halytsky Lviv National Medical University, Pharmacy M.D. Lubov Petrukh.
To study the antimicrobial activity of experimental compounds fluorene used test bacterial cultures of the Museum of Microbiology of Danylo Halytsky Lviv National Medical University, and Staphylococcus aureus ATCC 25923 (F/49), Staphylococcus epidermitidis 14490, Streptococcus pyogenes 2432, Escherichia coli ATCC 25922 (F-50), Klebsiella pneumoniae 1011, Pseudomonas aeruginosae ATCC 27853 / F-51). For cultivation of Streptococcus pyogenes used sugar broth with added 5-10% of horse serum and 5% blood agar. For the rest of the above bacterial cultures used beef extract agar and and Hottinger broth .
The sensitivity of bacteria to fluorene compounds studied in Mueller-Hinton medium by conventional methods.
Our studies have etablished (table 1), that the new synthesized compounds of fluorene Fl 4; P6; P7 have selective antibacterial activity. Thus, the coccal flora their activity is within 31,25-62,5 mkg / ml. Gram-negative bacteria such as Escherichia coli ATCC 25922 (F-50), Klebsiella pneumoniae 1011, Pseudomonas aeruginosae ATCC 27853 / F-51, were resistant to the compounds of fluorene.
Antibacterial activity of fluorene derivatives
E. coli 25922/
It was established that the new compound fluorene derivatives Fl4, P6, P7, have high antibacterial action to Gram-positive bacteria Staphylococcus aureus ATCC 25923 (F/49), Staphylococcus epidermitidis 14490, Streptococcus pyogenes 2432 was 31-25-62,5 mkg / ml Against gram-negative bacteria studied compounds were not active.
Thus the fluorene derivatives are promising for making dosage forms for the treatment of staphylococcal and streptococcal infections.
The stated necessitates a targeted search and development of new antimicrobial agents with high activity against gram-negative and gram-positive pathogens, low toxicity, acceptable physical and chemical properties of the relatively slow formation to their resistance in microbes.